1st Circ. Won't Rethink Nexium Pay-For-Delay Decision

Law360, New York (January 10, 2017, 5:52 PM EST) -- The First Circuit on Tuesday turned down bids by Nexium buyers for a rehearing of its November decision declining to revive a pay-for-delay class action against AstraZeneca and Ranbaxy over the heartburn medication.

End payors, direct purchasers and individual retailers had all asked the appeals court for either a rehearing by the original three-judge panel or a full-panel review of the case, but none of their requests had merit, the court said.

The direct purchasers and end payors had argued that the court’s ruling created a requirement for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.